BEI
CRDL

Benjamin Edwards Inc’s Cardiol Therapeutics CRDL Stock Holding History

Benjamin Edwards Inc’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-875
Closed -$2K – 1106
2024
Q2 		$2K Hold
875
– – ﹤0.01% 658
2024
Q1 		$2K Hold
875
– – ﹤0.01% 690
2023
Q4 		$1K Hold
875
– – ﹤0.01% 625
2023
Q3 		$1K Hold
875
– – ﹤0.01% 625
2023
Q2 		$1K Hold
875
– – ﹤0.01% 652
2023
Q1 		$0 Hold
875
– – ﹤0.01% 701
2022
Q4 		$0 Hold
875
– – ﹤0.01% 732
2022
Q3 		$1K Buy
+875
New +$1.07K ﹤0.01% 675

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Benjamin Edwards Inc's CRDL Position: Q3 2024 in Review

Benjamin Edwards Inc sold out of Cardiol Therapeutics (CRDL) in Q3 2024, closing a stake of 875 shares — an estimated $2K sold.

Benjamin Edwards Inc first reported a position in CRDL in Q3 2022 and held it in 8 quarters. The position peaked at $2K in Q2 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q3 2024.

  • Benjamin Edwards Inc reported no remaining Cardiol Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Benjamin Edwards Inc sold 875 Cardiol Therapeutics shares in Q3 2024, an estimated $2K.
  • Benjamin Edwards Inc first reported a position in Cardiol Therapeutics in Q3 2022 and held it in 8 quarters.
  • Benjamin Edwards Inc's Cardiol Therapeutics position peaked at $2K in Q2 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2024.

Based on Benjamin Edwards Inc's 13F filing for Q3 2024, filed 14 Nov 2024.